Charles River Frontage Acquisition: Charles River Laboratories to Buy Frontage’s Bioanalysis and DMPK Businesses for About $470 Million
Charles River Laboratories (NYSE: CRL) has agreed to acquire Frontage Holdings’ bioanalysis and DMPK operations in Exton, Pennsylvania for about $470 million in cash, plus up to $75 million in contingent payments. Closing is expected in the first half of 2027.
